Evidence and analysis
Research evidence pack
Source-backed valuation visuals
2. Company Fundamentals
2.3 Management
| Role | Metric |
|---|---|
| Consensus Rating | N/A |
2.4 Return
| Metric | Value |
|---|---|
| Expected Return (Ann.)* | 133035.81% |
| Risk / Std Dev (Ann.)* | 821.89% |
| 1-Year Price Return* | 102.93% |
Latest Market Data (as of 2026-08-06, Hong Kong time):
| Metric | Value |
|---|---|
| Last Price | HK$0.485 |
| 52-Week Range | HK$0.15 – HK$2.33 |
| Observation Count | 245 trading days |
The return and risk statistics use daily adjusted closes from the retrieved one-year price series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.
DuPont Model Analysis
The DuPont model decomposes return on equity (ROE) into three operating and capital-structure drivers:
ROE = Net Margin × Asset Turnover × Equity Multiplier
The comparison uses the latest two comparable annual periods available for the issuer, with reported statement amounts shown in HK$. Revenue and net income are income-statement flows; total assets and shareholders’ equity are year-end balance-sheet figures. This is a simplified year-end-balance DuPont comparison rather than an average-balance ROE calculation.
| DuPont component | Calculation | FY2025 | FY2024 |
|---|---|---|---|
| Revenue | Reported revenue | HK$377.17M | HK$370.07M |
| Net income | Reported net income | HK$-14.62M | HK$-44.21M |
| Total assets | Year-end reported balance | HK$214.66M | HK$209.50M |
| Shareholders’ equity | Year-end reported balance | HK$-91.08M | HK$-79.25M |
| Net margin | Net income ÷ revenue | -3.88% | -11.95% |
| Asset turnover | Revenue ÷ total assets | 1.7571x | 1.7665x |
| Equity multiplier | Total assets ÷ shareholders’ equity | -2.3568x | -2.6434x |
| ROE | Net margin × asset turnover × equity multiplier | 16.06% | 55.79% |
Source: Yahoo Finance annual statements. Values are based on the two latest comparable annual periods returned by the source; fiscal period labels use the statement period-end year.
2.5 FCFF DCF Valuation
FCFF DCF exception: The modelled terminal-year FCFF is non-positive, so a perpetuity valuation would not be reliable. This post deliberately does not publish a mechanical enterprise value or implied per-share value on an unsuitable basis.
| Available valuation input | Value |
|---|---|
| Last market price | HK$0.41 |
| Market capitalisation | HK$159.49M |
| Revenue | HK$377.17M |
| EBIT | HK$4.72M |
| Reported free cash flow | -HK$24.59M |
| FCF yield | -15.42% |
| Net debt / EBITDA | 4.95x |
2.6 Investor-Style Research Screen
| Educational screen | Result |
|---|---|
| Buffett-inspired cash-quality checks | not rated — FCFF DCF suitability or data-integrity condition not met |
| Lynch-inspired balance-and-growth checks | not rated — FCFF DCF suitability or data-integrity condition not met |
Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 16:31:31.754980 UTC; latest reported fiscal period: 2025-06-30 00:00:00. Financial institutions and REITs require sector-specific methods rather than a mechanical FCFF DCF. This is research and analysis only, not personalized financial advice.
2.7 Quantitative Factor Diagnostics
Model basis: Daily issuer USD excess returns are regressed in-sample using ordinary least squares on matching regional Fama–French factors. FF3 estimates market, size, and value loadings; FF5 adds profitability and investment. Coefficients are descriptive historical exposures, not predictions.
| Estimation input | Value |
|---|---|
| Regional factor set | Asia Pacific ex Japan |
| Factor-return currency | USD |
| Issuer-return basis | USD adjusted total return |
| Estimation window | 2025-08-20 to 2026-06-30 |
| Aligned daily observations | 210 |
| Minimum observation requirement | 120 |
| Currency conversion for HK listings | HKD adjusted close divided by daily USD/HKD close before simple daily return calculation |
Fama–French Three-Factor and Five-Factor Results
| Diagnostic | FF3 | FF5 |
|---|---|---|
| Annualised alpha | 218,635.58% | 168,059.36% |
| Adjusted R² | -0.01 | -0.02 |
| Annualised residual volatility | 881.95% | 881.31% |
| Factor loading (t-statistic) | FF3 | FF5 |
|---|---|---|
| Market excess return (Mkt-RF) | 4.80 (0.95) | 5.89 (1.08) |
| Size (SMB) | 5.18 (0.70) | 7.99 (0.86) |
| Value (HML) | 2.03 (0.29) | 0.93 (0.12) |
| Profitability (RMW) | NM | -0.65 (-0.07) |
| Investment (CMA) | NM | 6.03 (0.54) |